Clinical trial
Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer
NCT00493376 · British Columbia Cancer Agency, Other · Terminated
Key facts
| NCT number | NCT00493376 |
|---|---|
| Title | Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer |
| Official title | Prospective Study of Tirapazamine Targeting in Cervical Cancer |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) |
| Status | Terminated |
| Study type | Observational |
| Conditions | Cervix Cancer |
| Intervention type | Procedure |
| Interventions | Cervical tissue biopsy analysis: Comet assay, Biopsy: Measurement of histone gamma H2AX phosphorylation, Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha, Measurement of vascular perfusion: contrast enhanced MRI |
| Enrollment | 1 |
| Start date | Aug 1, 2007 |
| First posted | Jun 28, 2007 |
| Last update posted | Feb 2, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: